Stockwinners Market Radar for August 09, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:29 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Twitter (TWTR) has approached TikTok's Chinese owner ByteDance to express interest in acquiring the U.S. operations of the video-sharing app, Reuters' Greg Roumeliotis and Kanishka Singh reported, citing two people familiar with the matter. It is far from certain that Twitter would be able to outbid Microsoft (MSFT) and complete such a transformative deal in the 45 days that President Donald Trump has given ByteDance to agree to a sale, the sources said. Meanwhile, NPR's Bobby Allyn reported that TikTok is planning to sue the Trump administration, challenging President Trump's executive order banning the service from the United States. The video-sharing app will file the federal lawsuit as soon as Tuesday, according to a person familiar with the matter. NPR has learned that the lawsuit will argue that President Trump's far-reaching action is unconstitutional because it failed to give the company a chance to respond. It also alleges that the administration's national security justification for the order is baseless, according to the source. 2. Simon Property Group (SPG), the biggest mall owner in the U.S., has been in talks with Amazon (AMZN) to turn some of its anchor department-store spaces into Amazon fulfillment centers, The Wall Street Journal's Esther Fung and Sebastian Herrera reported, citing people familiar with the matter. Simon's discussions with the online retailer have been under way for months and began before the coronavirus pandemic, the people said. The two companies have explored converting stores formerly occupied by J.C. Penney (JCP) and Sears (SHLD) into Amazon distribution centers; in some cases, Simon and Amazon explored buying out occupied space from the retailers, sources added. 3. Apple (AAPL) shares came tantalizingly close to the historic $2T threshold this past week, Barron's Eric Savitz wrote in this week's edition of Barron's. For years, bulls asserted that Apple shares looked cheap on most typical valuation metrics, but the rally has driven the stock to its highest level in at least a decade based on whatever metric you want to use: price to earnings, price to sales, price to book, the author noted. Nonetheless, with Shopify (SHOP) trading for 50 times sales, Zoom Video (ZM) trading for 40 times and Microsoft trading for 10 times sales, Apple at $2T is no longer cheap but also not crazy, the report contended. 4. Qualcomm (QCOM) is lobbying the Trump administration to roll back restrictions on the sale of advanced components to Huawei Technologies, wading into the intensifying technology battle between the U.S. and China, The Wall Street Journal's Asa Fitch and Kate O'Keeffe reported. Qualcomm is telling U.S. policy makers their export ban won't stop Huawei from obtaining necessary components and just risks handing billions of dollars of Huawei sales to the U.S. firm's overseas competitors, according to a presentation reviewed by The Wall Street Journal that the company has been circulating around Washington. 5. Estee Lauder (EL), Lennar (LEN; LEN.B), Brown Forman (BF.A; BF.B), Liberty Broadband (LBRDA; LBRDK), Liberty Formula One (FWONA; FWONK) saw positive mentions in this week's edition of Barron's.

15:39 EDT ON Semiconductor to explore sale of Niigata Manufacturing Facility - ON Semiconductor announced it is exploring a sale of its manufacturing facility in Niigata, Japan. The intended sale of Niigata facility is part of the company's plan to optimize its manufacturing footprint and sharpen its focus on highly differentiated power, analog and sensor products. The company will begin searching for strategic buyers to enter into a mutually beneficial arrangement that is expected to facilitate an orderly transition of products from its facility in Niigata to other facilities in its network.

15:31 EDT Majesco enters into amended agreement to be acquired by Thoma Bravo - Majesco announced that it has signed an amended definitive agreement to be acquired by Thoma Bravo in a transaction valuing the company at $729M. Following the closing of the transaction, Majesco will operate as a privately held company. Under the amendment, Thoma Bravo will acquire all of Majesco's outstanding shares for $16.00 per share. The price represents a premium of approximately 113% over Majesco's average closing price of $7.52 during the 30-trading day period ended July 17, 2020. The proposed merger is subject to the approval of Majesco shareholders and the approval of the shareholders of Majesco's parent company, Majesco Limited. Majesco's and Majesco Limited's Boards of Directors have unanimously approved the merger and recommend that their respective shareholders approve the merger. Majesco Limited's promoter shareholders have entered into a voting agreement to vote in favor of a transaction with Thoma Bravo and against a competing transaction, which remains in place for a 7-month period following any termination of the transaction documents. Majesco will solicit written consents from its shareholders to approve the Merger Agreement and expects to distribute the consent solicitation statement in August 2020. The increased offer from Thoma Bravo and the amendment followed Majesco's receipt of an unsolicited acquisition proposal from an unaffiliated third party. Completion of the merger is not subject to a financing condition but is subject to the accuracy of the representations and warranties, performance of the covenants and other agreements included in the Merger Agreement and customary closing conditions for a transaction of this type, including regulatory approvals in the U.S. and India. Assuming satisfaction of those conditions, the company expects the merger to close by the end of 2020.

15:19 EDT Bristol-Myers says Opdivo plus Yervoy demonstrates durable survival benefit - Bristol Myers Squibb has announced that "Opdivo plus Yervoy demonstrated a significant improvement in overall survival in patients with previously untreated, unresectable malignant pleural mesothelioma in the Phase 3 CheckMate -743 clinical trial." With a minimum follow-up of 22 months, treatment with Opdivo plus Yervoy reduced the risk of death by 26%, demonstrating a median OS of 18.1 months versus 14.1 months for platinum-based standard of care chemotherapy. At two years, 41% of patients treated with the Opdivo plus Yervoy combination were alive, compared to 27% of patients treated with chemotherapy. The safety profile of Opdivo plus Yervoy was consistent with previously reported studies, and no new safety signals were observed. Histology is a well-established prognostic factor in mesothelioma, with non-epithelioid patients generally experiencing poorer outcomes. In CheckMate -743, Opdivo plus Yervoy showed improvements in survival across both non-epithelioid and epithelioid MPM, with a larger magnitude of benefit observed in the non-epithelioid subgroup. With the dual immunotherapy combination, median OS was 18.7 months for epithelioid patients and 18.1 months for non-epithelioid patients, compared to 16.5 months and 8.8 months, respectively, with chemotherapy. Opdivo plus Yervoy is a unique combination of two immune checkpoint inhibitors that features a potentially synergistic mechanism of action, targeting two different checkpoints to help destroy tumor cells: Yervoy helps activate and proliferate T cells, while Opdivo helps existing T cells discover the tumor. Some of the T cells stimulated by Yervoy can become memory T cells, which may allow for a long-term immune response.